ReviewRheumatology international2026
Effectiveness of tocilizumab monotherapy for IgG4-related disease-like features caused by idiopathic multicentric Castleman's disease: a case-based review.
Review in Rheumatology international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Idiopathic multicentric Castleman's disease (iMCD) and immunoglobulin G4-related disease (IgG4-RD) are distinct systemic inflammatory diseases that can exhibit overlapping clinical manifestations, including elevated serum IgG4 levels and tissue infiltration of IgG4-positive plasma cells. Although interleukin-6 (IL-6) inhibitors are established first-line therapies for iMCD, optimal treatment strategies for cases of iMCD with IgG4-RD-like features remain unestablished, particularly regarding whether glucocorticoids are essential or not. Herein, we report our case of iMCD with IgG4-RD-like features successfully treated with tocilizumab monotherapy. A 68-year-old female presented with dyspnea due to a recurrent laryngeal tumor, accompanied by pulmonary consolidation, mediastinal and axillary lymphadenopathy, sclerosing mesenteritis, and retroperitoneal fibrosis. Laboratory evaluation revealed elevated C-reactive protein (CRP) and serum IgG4 levels. Although the organ involvement and elevated IgG4 levels were suggestive of IgG4-RD, and laryngeal and pulmonary specimens exhibited IgG4-positive plasma cell infiltration, histopathological examination of lymph node confirmed the diagnosis of iMCD; therefore, we diagnosed the patient with iMCD with IgG4-RD-like features. Tocilizumab monotherapy achieved rapid normalization of CRP and IgG4 levels, along with improvement of organ involvements. The patient attained long-term clinical remission without glucocorticoids. Our literature review identified 9 previously reported cases of iMCD with IgG4-RD-like features. Eight of nine cases showed an insufficient response to initial glucocorticoid monotherapy and subsequently required the addition of IL-6 targeting agents to obtain disease resolution. Together with the findings from our literature review, our case suggests that tocilizumab monotherapy may be a potential treatment option for IgG4-RD-like features caused by iMCD.
Indexed as
Identifiers
42911255What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.